Role of imaging biomarkers in mutation-driven non-small cell lung cancer

doi:10.5306/wjco.v11.i7.412

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7618)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-4) series.

Item

Count

PDF

401

WORD

186

HTML

3517

Figures (1-7)

487

Tables (1-4)

268

Sum=4859

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

296

Download

563

Sum=859

Publishing Process of This Article

Item

Count

Browse

724

Download

1176

Sum=1900

Jul 24, 2020 (publication date) through May 25, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Jul 24, 2020; 11(7): 412-427
Published online Jul 24, 2020. doi: 10.5306/wjco.v11.i7.412

Table 1 Targetable genotypes in non-small cell lung cancer with Food and Drug Administration-approved targeted therapies

Molecular alteration	Approved targeted therapies
EGFR	Afatinib
	Dacomitinib
	Erlotinib
	Gefitinib
	Osimertinib
ALK	Alectinib
	Brigatinib
	Ceritinib
	Crizotinib
	Lorlatinib
ROS1	Crizotinib
ROS1	Entrectinib
BRAF	Dabrafenib + trametinib
NTRK	Larotrectinib
NTRK	Entrectinib

EGFR: Epidermal growth factor receptor; ALK: Anaplastic lymphoma kinase; ROS1: c-ROS oncogene 1; NTRK: Neurotrophic receptor tyrosine kinase.

Citation: Mendoza DP, Piotrowska Z, Lennerz JK, Digumarthy SR. Role of imaging biomarkers in mutation-driven non-small cell lung cancer. World J Clin Oncol 2020; 11(7): 412-427
URL: https://www.wjgnet.com/2218-4333/full/v11/i7/412.htm
DOI: https://dx.doi.org/10.5306/wjco.v11.i7.412